Sii Investments Inc. WI Has $843,000 Stake in Celgene Corporation (CELG)

Sii Investments Inc. WI raised its stake in Celgene Corporation (NASDAQ:CELG) by 0.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 6,809 shares of the biopharmaceutical company’s stock after buying an additional 2 shares during the period. Sii Investments Inc. WI’s holdings in Celgene Corporation were worth $843,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of CELG. State Street Corp boosted its stake in shares of Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. boosted its stake in shares of Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Celgene Corporation by 4.3% in the first quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock valued at $446,406,000 after buying an additional 147,263 shares in the last quarter. 78.41% of the stock is currently owned by institutional investors.

Celgene Corporation (NASDAQ CELG) traded up 0.18% during midday trading on Friday, reaching $130.61. 2,735,623 shares of the company’s stock traded hands. The firm’s 50-day moving average is $134.14 and its 200 day moving average is $124.30. The firm has a market cap of $102.18 billion, a PE ratio of 40.45 and a beta of 1.89. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 earnings per share. Equities research analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sii Investments Inc. WI Has $843,000 Stake in Celgene Corporation (CELG)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/sii-investments-inc-wi-has-843000-stake-in-celgene-corporation-celg.html.

CELG has been the topic of several analyst reports. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price objective (up previously from $150.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.93 to $160.00 in a research note on Monday, July 31st. Credit Suisse Group set a $148.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. Finally, Cann reissued a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average price target of $147.00.

In other news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now owns 76,301 shares in the company, valued at $10,264,010.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply